Abstract: Described are methods for providing personalized medicine for the treatment of B cell malignancies including lymphoma. The methods make use of Chimeric Antigen Receptor (CAR) technology.

Abstract: A combination pre-roll container and chillum device comprises a cylindrical member; a bowl at a first end of the cylindrical member for holding a smokable substance; a mouthpiece at a second end of the cylindrical member for drawing air; and a lumen fluidly connecting the bowl and mouthpiece so that smoke from burning smokable substance can be inhaled through the mouthpiece. The lumen includes a region of reduced dimensions so that smoke can pass, while helping to prevent the smokable substance from further entering the lumen. A first cap is positionable on the first end to cover the bowl and a second cap is positionable on the second end to cover the mouthpiece. The lumen is an airtight container for the pre-roll and smokable substance in the bowl is protected with the first cap positioned on the first end and the second cap positioned on the second end.

Abstract: The present disclosure provides human antibodies and fragments thereof having binding specificity to the SARS-CoV-2 spike protein's receptor binding domain (RBD). The antibodies and fragments have strong affinity and potent neutralization ability against the SARS-CoV-2 virus and various mutant forms. Also provided are trimeric antibodies which have further enhanced neutralization capabilities. The antibodies and fragments thus may be used for preventing or treating SARS-CoV-2 viral infection or detecting the presence of the virus in a sample.

Abstract: Described are methods for providing personalized medicine for the treatment of B cell malignancies including lymphoma. The methods make use of Chimeric Antigen Receptor (CAR) technology.

Abstract: Disclosed herein are methods of labeling organic compounds without depending on any functional group of the compound. In some embodiments, provided are bifunctional linkers useful in the methods.

Abstract: Described are methods for providing personalized medicine for the treatment of B cell malignancies including lymphoma. The methods make use of Chimeric Antigen Receptor (CAR) technology.

Abstract: Described are methods for providing personalized medicine for the treatment of B cell malignancies including lymphoma. The methods make use of Chimeric Antigen Receptor (CAR) technology.

Abstract: The invention provides TrkB agonist antibodies or antigen-binding fragments that specifically enhance TrkB signaling activities. The invention also provides therapeutic methods of using such antibodies for promoting survival and regeneration of retinal ganglion cells, and for treating or preventing subjects suffering from or at risk of developing various neurodegenerative conditions such as glaucoma.

Abstract: The present invention provides methods for generating functional derivatives of effector polypeptides (e.g., hormones and receptor ligands) embedded in a different protein scaffold (e.g., antibody scaffolds). The methods involve modifying the effector polypeptide with a combinatorial library of terminal linker sequences, inserting the modified sequences into the host scaffold, and then selecting functional derivatives from the library of modified polypeptide sequences embedded in the host scaffold. As exemplifications, the invention also provides specific functional derivatives of leptin, scFSH and scRelaxin embedded in an antibody scaffold, as well as therapeutic applications of such functional fusion molecules.

Abstract: Described are methods for providing personalized medicine for the treatment of B cell malignancies including lymphoma. The methods make use of Chimeric Antigen Receptor (CAR) technology.

Abstract: Described are methods for providing personalized medicine for the treatment of B cell malignancies including lymphoma. The methods make use of Chimeric Antigen Receptor (CAR) technology.

Abstract: Described are methods for providing personalized medicine for the treatment of B cell malignancies including lymphoma. The methods make use of Chimeric Antigen Receptor (CAR) technology.

Abstract: The invention provides combinatorial peptide or polypeptide libraries that can become membrane tethered once expressed in cells. The invention additionally provides methods for selecting peptide modulators (e.g., agonists) of GPCRs from the combinatorial libraries of the invention. The invention also provides novel GPCR polypeptide modulators, e.g., biased polypeptide agonists of the glucagon-like peptide 1 receptor (GLP-1R). The invention further provides methods of promoting insulin sensitivity, lowering blood glucose, and reducing body weight as well as methods for treating various diseases such as diabetes and obesity.

Abstract: The invention provides variant venom peptides and polypeptides that specifically block potassium voltage gated ion channel Kv1.3. The invention also provides methods of inhibiting Kv1.3 channel activity, methods for treating disorders that are associated with undesired or aberrant Kv1.3 channel activity, methods for detecting Kv1.3 expression in target cells such as lymphocytes, and methods for diagnosing diseases or disorders that are associated with aberrant Kv1.3 overexpression.

Abstract: The invention provides methods for identifying binding partners (e.g., peptide ligands) that binds to a target protein (e.g., a cellular receptor). The methods entail co-localized expression of the target protein and candidate binding partners, and selection of binding partners based on their proximity in the plasma membrane.

Abstract: The Invention provides in vivo selection methods for identifying modulating agents (e.g., antibodies or polypeptides) that promote cellular differentiation and migration. The methods utilize a combinatorial agent library (e.g., antibodies expressed via lentiviral vectors) that are expressed in a population of to-be modulated cells (e.g., stem cells), which are then introduced into, the body of a non-hum an animal (e.g., mouse). This is followed by examining an organ or tissue of interest (e.g., brain) of the manipulated animal for the presence of a modulating agent and/or a specific phenotype. The; invention also provides specific antibody agent, that can induce differentiation of stem cells into microglia and migration into the brain. Further provided in the invention are therapeutic applications of the microglia-inducing antibodies.

Abstract: The invention provides methods for identifying protein modulators (e.g., antibody agonists) of eukaryotic cells. The methods typically involve expressing a combinatorial agent library (e.g., via lentiviral vectors) inside a eukaryotic cell type (e.g., a mammalian cell) and then directly selecting for agents (e.g., antibodies) that are agonist of a target molecule (e.g., a signaling receptor) that modulates a phenotype of or elicits a cellular response in the cell. Some related methods involve co-culturing a cell expressing a combinatorial agent library and a second cell, and then selecting agents that modulate a phenotype of or elicit a cellular response in the second cell. Preferably, the agents are antibodies and are introduced into and expressed in the starting cells under conditions each individual cell expresses no more than 3 different members of the antibody library.

Abstract: An apparatus includes beam shearing optics situated to receive a collimated beam and to shear the collimated beam along a first direction so as to form a plurality of adjacent collimated beam portions, and homogenization optics situated to receive and homogenize the adjacent collimated beam portions along at least the first direction so as to produce a homogenized output beam. A method includes shearing a collimated beam having a beam parameter product (bpp) along an axis so as to form a plurality of sheared collimated beam portions, and arranging the sheared collimated beam portions adjacent to each other so that a line beam having a length and thickness that is formed with the light from the sheared collimated beam portions has a lower bpp associated with the line beam thickness than the bpp of the collimated beam along the axis.

Abstract: Embodiments described herein relates to compositions and methods of preventing and/or treating itch in a subject using a therapeutically effective amount of a MRG receptor antagonist. e.g., a tripeptide QWF. In one embodiment, the itch is a non-histamine mediated itch.

Abstract: The invention provides TrkB agonist antibodies or antigen-binding fragments that specifically enhance TrkB signaling activities. The invention also provides therapeutic methods of using such antibodies for promoting survival and regeneration of retinal ganglion cells, and for treating or preventing subjects suffering from or at risk of developing various neurodegenerative conditions such as glaucoma.